GlobeNewswire

MSAB launches new rapid triage extraction solution for immediate actionable intel in the field

Share

MSAB announces the launch of Raven, an innovative solution for immediate digital evidence acquisition and analysis at scene level via smartphone app.
Raven is a cutting edge, highly portable mobile device extraction toolset. It is specifically designed for operators in the field who need lightweight solutions to quickly extract data and turn it into actionable intelligence. “To the best of my knowledge, having such a powerful lightweight technology is entirely unique”, says Joel Bollö, CEO of MSAB.

“Digital evidence captured at the scene of an incident from witnesses and victims consistently contains critical insights. But no one wants to surrender their mobile phones and have to be without them till labs extract the evidence days or weeks later.” Says Jansen Cohoon, MSAB Product Specialist for Raven and President of MSAB in North America. “To combat this, frontline practitioners need to be equipped with solutions in the field to extract consent-based digital evidence quickly and easily. This is where Raven comes into its own. A unique solution for timely access to critical evidence and intelligence.”

Raven is a collection of applications (apps) that run on Android OS devices including mobile phones and tablets. Built on top of the latest Android operating system as a collection of applications and compatible hardware, Raven allows a user to take advantage of a standard Android device’s capabilities and enhance them with advanced forensic data collection capabilities, simply by downloading all or selected Raven apps.

The Raven app suite consists of: MobEX (mobile device extraction); SIMEX (SIM card extraction); FlashEX (Flash media extraction); and DronEX (Drone device extraction). Plus, the ODIN analysis app allows users to quickly view the extracted results, check watch lists, find the most recent location data, and more.

“Putting such a powerful tool into the hands of frontline users will allow them to both speedily examine the digital evidence, which in turn will lead to faster apprehensions, and also enable them to engage with the public in a meaningful and respectful way. This also gives the community and its citizens agency and helps build public trust.” Jansen added.
MSAB Raven is available today to qualified law enforcement and defense agencies. For more information, please visit msab.com/raven

For more information, please contact:
Joel Bollö, CEO MSAB, joel.bollo@msab.com, +46 8739 0270
Jansen Cohoon, President of MSAB North America, jansen.cohoon@msab.com, +17037894717

About MSAB

MSAB is a world leader in forensic technology for extracting and analyzing data in seized mobile devices. The company develops high-quality and easy-to-use software for law enforcement organizations, such as police, military, and customs. The products, which have become a de facto standard for securing evidence in criminal investigations, can be supplemented with reporting tools and a large range of training with certifications within a holistic method for forensic science. The company serves customers in more than 100 countries worldwide, through its own sales offices and through distributors. MSAB is listed on Nasdaq Stockholm under the ticker name: MSAB B. www.msab.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Scientists Narrow Search For Mysterious Mad Trapper To Sweden30.7.2021 23:21:41 CEST | Press release

EDMONTON, Alberta and HOUSTON, July 30, 2021 (GLOBE NEWSWIRE) -- This month marks the 90th anniversary of the arrival of the fugitive known as ‘The Mad Trapper of Rat River’ to the Canadian North and the revelation of an important new clue to identifying the mysterious fugitive. Following the unprovoked shooting of RCMP Constable A.W. King in December 1931, the unknown criminal who identified himself by the pseudonym Albert Johnson led an RCMP posse on seven-week manhunt across the desolate Arctic landscape. During the pursuit, the Mad Trapper shot and killed Constable E. Millen. With the help of indigenous guides the Mad Trapper was located and killed during a gun battle on the Eagle River on February 17, 1932. Despite the RCMP releasing photos of the Mad Trapper and receiving hundreds of tips from around the world his identity was never established In 2007, Myth Merchant Films of Alberta Canada secured permission for a team of forensic experts to exhume the body of the Mad Trapper in

KBC Group: KBC remains strongly capitalised under 2021 EU-wide EBA stress test30.7.2021 18:15:00 CEST | Press release

Press Release Outside trading hours - Regulated information* Brussels, 30 July 2021 (6.15 p.m. CEST) KBC remains strongly capitalised under 2021 EU-wide EBA stress test KBC notes the announcements made today by the European Banking Authority (EBA) regarding the results of the 2021 EU-wide stress test. A brief set of slideson the KBC data is available at www.kbc.com. The impact of the stress test on KBC’s fully loaded Common Equity Tier-1 (CET1) ratio of 17.58% at year-end 2020 caused this ratio to increase by 1.92 percentage points to 19.50% at year-end 2023 under the base scenario. Under the adverse scenario, KBC’s fully loaded CET1 ratio would fall by 3.51 percentage points to 14.07%1. KBC’s leverage ratio, which stood at 6.42% at year-end 2020, would increase to 7.09% under the base scenario and decrease to just 5.53% under the adverse scenario. Commenting on today’s announcements, Johan Thijs, KBC Group CEO had this to say: ‘The results of this regular, theoretical exercise conduct

EBA reports on outcome of 2021 EU-wide stress test30.7.2021 18:10:23 CEST | Press release

EBA reports on outcome of 2021 EU-wide stress test ING Group was subject to the 2021 EU-wide stress test conducted by the European Banking Authority (EBA), in cooperation with the European Central Bank (ECB), the European Systemic Risk Board (ESRB) and De Nederlandsche Bank. ING Group notes the announcements made today by the EBA on the stress test and fully acknowledges the outcomes of this exercise. The 2021 EU-wide stress test does not contain a pass/fail threshold and instead is designed to be used as an important source of information for the purposes of the Supervisory Review and Evaluation Process. The results will assist competent authorities in assessing ING Group’s ability to meet applicable prudential requirements under stressed scenarios. The adverse stress test scenario was set by the ECB/ESRB and covers a three-year time horizon (2020-2023). The stress test has been carried out applying a static balance sheet assumption as at December 2020, and therefore does not take int

XBiotech Announces Payment of Dividend to Holders of Common Stock30.7.2021 17:03:00 CEST | Press release

Company distributed USD $75 Million to Shareholders AUSTIN, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00. Based on the number of shares of Common Stock issued and outstanding on the record date for the dividend, each such holder received USD$2.47 per share on July 23, 2021. In the past 18 months, XBiotech’s balance sheet strength has enabled the company to offer approximately USD$495 million in cash to shareholders by way of stock repurchase and dividend distribution. The financial strength of the Company owes to the successful development of a pipeline of True Human™ antibody drug candidates. John Simard stated that “XBiotech was pleased to be able to reward its shareholders with a $2.47 per share dividend. Our ability to continue to provide opportunities for shareholders to monetize stock in XBiotech, reflects the strength of

Jānis Buks elected as the Chairperson of the Management Board of JSC Olainfarm30.7.2021 12:41:00 CEST | Press release

Today, on July 30, the Supervisory Council of JSC Olainfarm has elected Jānis Buks as the Chairperson of the Management Board. He has significant professional experience, which, together with the team of JSC Olainfarm, will contribute to the company's growth, stability, and predictability. Jānis Buks was the Deputy Chairperson of the Supervisory Council of JSC Olainfarm from April 4, 2019 to June 17, 2021. “JSC Olainfarm is a Latvian pharmaceutical success story, however, the conflicts of recent years have overshadowed the success. We need to ensure stability and predictability, both for future plans and for the group as a whole. It is time to restart Olainfarm and build back the company's reputation, continue to grow and to be a stable and predictable partner and employer,” emphasizes Jānis Buks, Chairperson of the Management Board of JSC Olainfarm. J. Buks graduated from the Faculty of Law of the University of Latvia, obtaining a bachelor's degree in law. He improved his knowledge in

Arcadis reports transactions under its current share buyback program30.7.2021 12:00:00 CEST | Press release

Amsterdam, July 30, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, has repurchased 14,830 of its own shares in the period from 23 July up to and including 29 July 2021 at an average price of €36.99. The consideration of this repurchase was €0.5 million. The repurchase is in accordance with the share buyback program to cover existing obligations under employee incentive plans and to cover commitments for stock dividend, as announced on 19 February 2021. The total number of shares repurchased under this program to date is 1.7 million shares for a total consideration of €56.5 million. For more detailed information see: https://www.arcadis.com/en/global/investors/share-information/share-buyback-program/ -End- Improving quality of life FOR FURTHER INFORMATION PLEASE CONTACT: ARCADIS INVESTOR RELATIONS Jurgen Pullens Mobile: +31 6 51599483 E-mail: jurgen.pullens@arcadis.com ABOUT ARCADIS Arcadis is the leading global desig